StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$13.37M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$6.69M
EPS, diluted
-$1.21
Book value per share
$0.28
Diluted shares
6M

Trading

Previous close
$0.86
Open
$0.89
Day's range
$0.87 – $0.91
Volume
5,849
Average volume (20 days)
55,260
52-week range
$0.81 – $18.02
RSI (14 days)
29.1
Volatility (1 year)
125.7%
Relative volume
0.02×

Market cap history

Month-end market cap since 2016, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodMTNBS&P 500DifferenceMTNB per yearS&P 500 per year
1 month-61.6%-4.3%−57.3 pts
3 months-70.2%-4.6%−65.6 pts
Year to date-89.6%+7.9%−97.6 pts
1 year-94.9%+11.8%−106.7 pts
3 years-99.5%+68.0%−167.4 pts-82.7%+18.9%
5 years-99.9%+66.2%−166.1 pts-74.2%+10.7%
10 years-99.9%+291.3%−391.2 pts-51.0%+14.6%

Fourteen years at a glance

Fiscal years 2012 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$6.67M

Net income

-$6.69M

EPS, diluted

-$1.21

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Matinas BioPharma filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Matinas BioPharma

Pharmaceutical Preparations

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies utilizing its proprietary lipid nanocrystal delivery technology. The platform encapsulates small molecules and oligonucleotides to facilitate targeted, extrahepatic cellular delivery without toxicity, targeting applications in oncology and inflammation. The company's lead product candidate is MAT2203, an oral formulation of the potent antifungal agent amphotericin B engineered to treat life-threatening invasive fungal infections, including invasive aspergillosis, cryptococcal meningitis, and invasive candidiasis. The company develops these therapeutic candidates primarily for patients facing serious fungal infections who have limited or no alternative treatment options.

Company profile, executives and history

Matinas BioPharma stock: common questions

What is Matinas BioPharma's stock price?

MTNB closed at $0.91 on Nov 18, 2026, up 6.35% on the day. Over the past 52 weeks it traded between $0.81 and $18.02.

What is Matinas BioPharma's market cap?

Matinas BioPharma was worth $13.37M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is MTNB's P/E ratio?

Matinas BioPharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.21), so it has no meaningful P/E ratio.

Does Matinas BioPharma pay a dividend?

No. Matinas BioPharma has not paid a cash dividend over the last twelve months.

How has MTNB stock performed over the past year?

Including dividends, MTNB returned -94.9% over the past year, against +11.8% for the S&P 500.

Who are Matinas BioPharma's competitors?

Companies most similar to Matinas BioPharma by business, industry and size include ABUS, LIPO, SCYX, HIND, ANTX.

See a number that looks wrong?